Christensen O'Connor Johnson Kindness PLLC
Pyrimidine derivative
Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR.Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I):General formula (I): wherein,      
Daiichi Sankyo Company, Limited
C C C C A C C C C C A A A C C C C
C07D C07D C07D C07D A61K C07D C07D C07D C07B C07D A61K A61P A61P C07D C07D C07D C07D
inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional inventional inventional
Yamato Hidekazu Hidenobu Rie Satoshi Toshiharu Bitoku Yasuyuki
Suzuki Inoue Murafuji Inaba Muneoka Noji Takahashi Takeda